Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/7/2025

Alternative Antihypertensive Medications After Lisinopril-Induced Rash

First-Line Alternative Options

  • The American Heart Association recommends Angiotensin Receptor Blockers (ARBs) as the preferred alternative for patients who cannot tolerate ACE inhibitors due to rash or other side effects, with options including candesartan, losartan, or valsartan 1, 2
  • While ARBs have a different mechanism of action than ACE inhibitors, there is a small risk (2-17%) of cross-reactivity in patients who experienced angioedema with ACE inhibitors, according to the American College of Cardiology 3

Second-Line Alternative Options

  • The American College of Cardiology recommends Calcium Channel Blockers (CCBs) as an excellent alternative if ARBs are contraindicated or not tolerated, with dihydropyridine CCBs preferred for hypertension without specific comorbidities 4, 5
  • The American Heart Association suggests Thiazide or Thiazide-like Diuretics as effective alternatives, particularly in patients with volume overload, and can be used as monotherapy or in combination with other agents 4, 5
  • Beta-Blockers should be considered primarily in patients with specific comorbidities such as coronary artery disease or heart failure, according to the American College of Cardiology 4, 5

Special Considerations

  • For patients with heart failure, the American Heart Association recommends ARBs as first-line alternatives to ACE inhibitors, and beta-blockers and aldosterone antagonists should also be part of the regimen for heart failure with reduced ejection fraction 1, 6, 4, 7
  • For patients with chronic kidney disease, ARBs provide similar renoprotective effects as ACE inhibitors, and renal function and potassium levels should be monitored closely when initiating therapy, according to the American Heart Association 7, 6

Important Precautions

  • The American College of Cardiology advises avoiding combination therapy with ACE inhibitors and ARBs as this increases cardiovascular and renal risk without additional benefit 5

Monitoring Recommendations

  • The American Heart Association recommends assessing blood pressure, renal function, and electrolytes within 1-2 weeks after initiating ARB therapy, and paying particular attention to patients with diabetes, renal impairment, or low systolic blood pressure (<80 mm Hg) 6, 2